Opportunity Information: Apply for RFA NR 11 003
Apply for RFA NR 11 003
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Personalized Genomics for Symptom Management Bridging the Gaps from Genomic Discovery to Improved Health Outcomes (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.361 Nursing Research.
- This funding opportunity was created on Jan 11, 2011 and posted on Jan 11, 2011.
- Applicants must submit their applications by Apr 18, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $300,000.00 in funding.
- Eligible applicants include: Native American tribal organizations (other than Federally recognized tribal governments) City or township governments County governments For profit organizations other than small businesses Private institutions of higher education Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH National Institute of Nursing Research (NINR) funding opportunity titled "Personalized Genomics for Symptom Management: Bridging the Gaps from Genomic Discovery to Improved Health Outcomes (R01)" was designed to support research that connects genomic discoveries to real, measurable improvements in symptom prevention and relief for people living with chronic disorders. The core idea is to move beyond identifying genetic signals in the lab and instead show how genomic information can help explain why symptoms look so different from one person to another, and how that knowledge can be used to guide more personalized and effective symptom management strategies in clinical care.
This R01 call focuses on two main research directions. First, it seeks studies that examine how genomic variants contribute to the wide, well-documented differences between individuals in symptom onset, symptom sensitivity, symptom duration, and symptom severity. This includes work on how people respond differently to therapies and interventions intended to prevent, reduce, or eliminate symptoms. In other words, the program is interested in why two patients with the same chronic condition and similar treatment plans might have very different experiences of pain, fatigue, sleep disturbance, nausea, mood symptoms, cognitive changes, or other symptom clusters, and whether genetic variation helps explain that gap. Second, it explicitly asks applicants to consider non-genomic influences that may modify or moderate genetic effects. This includes environmental, behavioral, social, cultural, clinical, and other factors that can shape whether and how genomic risk or genomic protection actually shows up in the form of symptoms or treatment response. The emphasis on moderation acknowledges that genes rarely act alone and that symptom outcomes often reflect interactions among biology, context, and care.
The expected impact of the funded research is practical and patient-centered. NINR anticipated that results would strengthen the evidence base needed to identify individuals at highest risk for developing severe or persistent symptoms and to support the development or targeting of customized therapeutics and interventions aligned with an individual's genomic profile. In applied terms, that could mean better risk stratification (spotting who is most likely to suffer intense symptoms), better matching of interventions to patients (choosing strategies more likely to work for a particular subgroup), and more efficient symptom control over the course of chronic illness, including during long-term treatment and survivorship. Because the institute is focused on nursing research, the underlying orientation is toward improving symptom science, symptom assessment, and symptom management in ways that can be implemented in real health settings, not just generating genomic associations without a pathway to improved outcomes.
Administratively, this was a discretionary NIH grant opportunity using the R01 research project grant mechanism, with no cost sharing or matching requirement. The opportunity was posted on January 11, 2011, with an application closing date of April 18, 2011, and it was later archived on May 19, 2011. The award ceiling listed is $300,000. Eligibility was broad and included public and private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) organizations), for-profit organizations (including small businesses), and multiple levels of government entities (state, county, city/township, special districts), as well as tribal governments and tribal organizations. The eligibility description also specifically mentions Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, and US territories or possessions. The program falls under CFDA 93.361 (Nursing Research).
Overall, the opportunity can be understood as an effort to accelerate "bench-to-bedside" translation in symptom management by integrating genomics with the broader set of influences that determine symptom burden and treatment response. Rather than treating symptoms as generic side effects or inevitable consequences of chronic illness, NINR used this R01 to push the field toward precision approaches that explain individual differences and lead to tailored interventions aimed at improving day-to-day functioning and long-term health outcomes.
Frequently Asked Questions (FAQs)
What is the title of this NIH/NINR funding opportunity?
The opportunity is titled "Personalized Genomics for Symptom Management: Bridging the Gaps from Genomic Discovery to Improved Health Outcomes (R01)."
Which NIH institute is sponsoring this opportunity?
This funding opportunity is sponsored by the NIH National Institute of Nursing Research (NINR).
What is the main purpose of this R01 opportunity?
The purpose is to support research that connects genomic discovery to real, measurable improvements in symptom prevention and relief for people living with chronic disorders, with an emphasis on translating findings into symptom management strategies that can be used in clinical care.
What does "bridging the gaps from genomic discovery to improved health outcomes" mean in this context?
It means moving beyond identifying genetic signals and showing how genomic information can help explain why symptoms vary from person to person and how that knowledge can be applied to personalize symptom management and improve patient-centered outcomes.
What grant mechanism is being used?
This is an NIH R01 research project grant opportunity.
Is cost sharing or matching required?
No. The opportunity specifies that there is no cost sharing or matching requirement.
When was the opportunity posted and when did it close?
It was posted on January 11, 2011, and the application closing date was April 18, 2011.
Is this funding opportunity still active?
No. The opportunity was later archived on May 19, 2011.
What is the listed award ceiling?
The award ceiling listed for this opportunity is $300,000.
Who is this opportunity intended to help, from a health perspective?
The research is aimed at improving symptom prevention and relief for people living with chronic disorders, particularly by addressing individual differences in symptom burden and treatment response.
What kinds of symptoms are within scope?
The description highlights symptoms and symptom clusters such as pain, fatigue, sleep disturbance, nausea, mood symptoms, and cognitive changes, as well as other symptom clusters experienced in chronic conditions.
What are the two main research directions emphasized by this R01 call?
First, studies examining how genomic variants contribute to differences in symptom onset, sensitivity, duration, and severity, including differences in response to therapies and interventions. Second, studies that consider non-genomic influences that may modify or moderate genetic effects on symptoms or treatment response.
What types of individual differences in symptoms is NINR interested in?
NINR is interested in genomic contributions to differences between individuals in symptom onset, symptom sensitivity, symptom duration, and symptom severity.
Does this opportunity include research on differences in treatment response?
Yes. It includes research on why people respond differently to therapies and interventions intended to prevent, reduce, or eliminate symptoms.
What does the opportunity mean by including non-genomic influences?
It means applicants are explicitly asked to consider environmental, behavioral, social, cultural, clinical, and other factors that can shape whether and how genomic risk or protection shows up in symptom outcomes or treatment response.
Why is the concept of "moderation" or "modification" important in this program?
The emphasis reflects the idea that genes rarely act alone and that symptom outcomes often result from interactions among biology, context, and care, so non-genomic factors may change the strength or direction of genetic effects.
What practical impact is NINR expecting from funded projects?
NINR anticipated patient-centered results that strengthen evidence for identifying individuals at highest risk for severe or persistent symptoms and that support development or targeting of customized therapeutics and interventions aligned with an individual's genomic profile.
How could this research affect clinical symptom management in real settings?
In applied terms, it could support better risk stratification (spotting who is most likely to experience intense symptoms), better matching of interventions to patients (choosing strategies more likely to work for certain subgroups), and more efficient symptom control over the course of chronic illness, including long-term treatment and survivorship.
Is this opportunity focused on basic genomic associations only?
No. The orientation is toward translation and implementation in real health settings, not generating genomic associations without a pathway to improved symptom outcomes.
How does this opportunity align with nursing research?
Because NINR is focused on nursing research, the opportunity emphasizes improving symptom science, symptom assessment, and symptom management in ways that can be implemented in clinical and real-world health settings.
What types of organizations are eligible to apply?
Eligibility is broad and includes public and private institutions of higher education; nonprofits (including 501(c)(3) and certain non-501(c)(3) organizations); for-profit organizations (including small businesses); and government entities at multiple levels (state, county, city/township, special districts), as well as tribal governments and tribal organizations.
Are minority-serving or mission-driven institutions specifically mentioned as eligible?
Yes. The eligibility description specifically mentions Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are specifically mentioned as eligible.
Are U.S. territories or possessions included in the eligibility list?
Yes. U.S. territories or possessions are specifically mentioned as eligible.
Are eligible federal agencies and regional organizations included?
Yes. Eligible federal agencies and regional organizations are specifically mentioned as eligible.
What is the CFDA number associated with this program?
The program falls under CFDA 93.361 (Nursing Research).
What does "bench-to-bedside" translation mean for this opportunity?
It refers to accelerating the movement from genomic discoveries (often made in laboratory or discovery contexts) into clinical applications that improve symptom management and health outcomes for people with chronic disorders.
Does the opportunity encourage precision or personalized approaches to symptom management?
Yes. It is explicitly oriented toward precision approaches that explain individual differences and lead to tailored interventions aimed at improving day-to-day functioning and long-term health outcomes.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Personalized Genomics for Symptom Management Bridging the Gaps from Genomic Discovery to Improved Health Outcomes (R21)
Previous opportunity: BJA FY 11 Capital Case Litigation Initiative
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA NR 11 003
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA NR 11 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| Personalized Genomics for Symptom Management Bridging the Gaps from Genomic Discovery to Improved Health Outcomes (R21) Apply for RFA NR 11 004 Funding Number: RFA NR 11 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Acute Life Threatening Conditions and Opportunities for Palliative and End of Life Care Research (R01) Apply for RFA NR 11 008 Funding Number: RFA NR 11 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Interdisciplinary Approaches for HIV/AIDS Risk Avoidance Decision Making in Developing Adolescents (R01) Apply for RFA NR 11 007 Funding Number: RFA NR 11 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Alzheimers Disease Pilot Clinical Trials (R01) Apply for PAR 11 100 Funding Number: PAR 11 100 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| U.S. India Bilateral Brain Research Collaborative Partnerships (U.S. India BRCP) (R21) Apply for PAR 11 099 Funding Number: PAR 11 099 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Increasing Opportunities in Advanced Heart Failure and Palliative Care Research (R01) Apply for RFA NR 11 006 Funding Number: RFA NR 11 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Reducing Health Disparities Among Minority and Underserved Children (R01) Apply for PA 11 104 Funding Number: PA 11 104 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Reducing Health Disparities Among Minority and Underserved Children (R21) Apply for PA 11 105 Funding Number: PA 11 105 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Lasker Clinical Research Scholars Program (SI2) Apply for RFA OD 11 001 Funding Number: RFA OD 11 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Pre Application for the 2011 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (X02) Apply for PAR 11 102 Funding Number: PAR 11 102 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| 2011 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (DP1) Apply for RFA DA 11 009 Funding Number: RFA DA 11 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44) Apply for RFA CA 11 002 Funding Number: RFA CA 11 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Predictive Animal Models for Smoking Cessation Medications (U54) Apply for RFA DA 11 014 Funding Number: RFA DA 11 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Centers for AIDS Research and Developmental Centers for AIDS Research (P30) Apply for PAR 11 108 Funding Number: PAR 11 108 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Grand Opportunity in Medications Development for Substance Related Disorders (U01) Apply for PAR 11 109 Funding Number: PAR 11 109 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (Parent F31) Apply for PA 11 111 Funding Number: PA 11 111 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NINR Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows In Nursing Research (F31) Apply for PAR 11 117 Funding Number: PAR 11 117 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition Specific pathogen free macaque colonies (U42) Apply for PAR 11 116 Funding Number: PAR 11 116 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition Specific pathogen free macaque colonies (U24) Apply for PAR 11 115 Funding Number: PAR 11 115 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV/AIDS Implementation Science Targeting Drug Using Populations A Collaboration with PEPFAR (R01) Apply for RFA DA 12 002 Funding Number: RFA DA 12 002 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA NR 11 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.